New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
08:04 EDTJAZZJazz Pharmaceuticals and Gentium announce Europcean launch of Defitelio
Jazz Pharmaceuticals and Gentium S.p.A., a Jazz Pharmaceuticals company, announced the commencement of the European commercial launch of Defitelio, the first licensed product for the treatment of severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.1 The companies have launched Defitelio in Germany and Austria and expect to continue the launch in 27 additional European countries on a rolling basis during 2014 and 2015.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
14:42 EDTJAZZJazz Pharmaceuticals management to meet with Canaccord
Group dinner to be held in New York on November 30 hosted by Canaccord.
07:33 EDTJAZZMylan launches Clozapine Orally Disintegrating Tablets in the U.S.
Mylan (MYL) announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo (JAZZ). Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
November 18, 2015
08:28 EDTJAZZLeerink to hold a bus tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use